HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.